title: [Hepatic steatosis in chronic hepatitis B: prevalence, risk factors, and impact on fibrosis and therapeutic response].
abstract: BACKGROUND
  steatosis is a common injury in chronic hepatitis C, but this association has not been sufficiently studied in chronic hepatitis B. aim: To evaluate the prevalence of hepatic steatosis in chronic hepatitis B and determine its association with various histologic, biochemical, virological, and metabolic diseases, and its effect on fibrosis and therapeutic response.
  
  
  METHODS
  Our study was compiled 133 patients with chronic hepatitis B who received no antiviral therapy and who had a liver biopsy. Our patients were divided into 2 groups: 51 patients (38.3%) had steatosis (Group I), while 82 (61.7%) had no steatosis (Group II).
  
  
  RESULTS
  In groupeI, the average age, BMI, cholesterol, triglycerides, and glucose were significantly higher than the group without steatosis in univariate study (P <0.05). In multivariate analysis, only high BMI and hypertriglyceridemia were included.No significant difference between the two groups was observed in the rate of transaminases, HBeAg status, viral load (P> 0.05). Steatosis doesn't influence fibrosis stage and therapeutic response.
  
  
  CONCLUSIONS
  During chronic hepatitis B, steatosis appears to be the result of metabolic factors of the host rather than the effect of the virus. Hepatic steatosis does not seem to influence the progression of liver fibrosis, or therapeutic response, however, the role of steatosis should be better studied by prospective longitudinal clinical studies on large populations of patients.
authors.forename: Aida
authors.initials: A
authors.lastname: Ben Slama Trabelsi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Ksiaa
authors.forename: Ahlem
authors.initials: A
authors.lastname: Souguir
authors.forename: Dhilel
authors.initials: D
authors.lastname: Issaoui
authors.forename: Badreddine
authors.initials: B
authors.lastname: Sriha
authors.forename: Salem
authors.initials: S
authors.lastname: Ajmi
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005234:Fatty Liver / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D016896:Treatment Outcome; D014416:Tunisia / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents; D007372:Interferons